Form 4: BeOne Medicines CEO John Oyler Sells Shares for Tax Withholding

BeOne Medicines Ltd. CEO John Oyler reported the sale of American Depositary Shares totaling approximately $830,989.96 for mandatory tax withholding purposes related to the vesting of restricted share units.

Summary

• John Oyler, the Chief Executive Officer and a Director of BeOne Medicines Ltd. (ONC), reported the sale of American Depositary Shares (ADS).
• The transactions occurred on June 23, 2025, and were made pursuant to a Rule 10b5-1(c) plan.
• A total of 3,074 ADS were sold at a price of $261.5712 per ADS, and an additional 100 ADS were sold at $262.9 per ADS.
• The aggregate value of the shares sold amounted to approximately $830,989.96.
• The sale was executed to fulfill mandatory tax withholding obligations associated with the vesting of a previously granted restricted share unit award.
• Each American Depositary Share represents 13 Ordinary Shares.
• Following the transactions, Mr. Oyler directly beneficially owns 8,173,759 Ordinary Shares.
• He also holds significant indirect beneficial ownership of Ordinary Shares through various entities, including 481,533 shares via the P&O Trust, 7,722,480 shares via a grantor retained annuity trust, 28,204,115 shares via Oyler Investment LLC, 9,545,000 shares via a Roth IRA PENSCO trust account, and 102,188 shares via The John Oyler Legacy Trust, disclaiming beneficial ownership for most of these indirect holdings.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's explicitly for mandatory tax withholding, a non-discretionary event, and was made under a 10b5-1 plan, which mitigates negative interpretations typically associated with insider sales.

Positives

• The sale was explicitly for mandatory tax withholding, indicating a non-discretionary reason rather than a voluntary divestment.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-arranged and transparent sale strategy.

Negatives

• The transaction represents a reduction in the direct beneficial ownership of American Depositary Shares by a key executive.

Risks

• While the sale was for tax purposes, any reduction in insider ownership, even if non-discretionary, could be perceived as a minor risk by some investors.

Future Outlook

The document indicates that 1/4th of the restricted share units will vest on each anniversary of June 22, 2022, subject to continued service, with accelerated vesting possible upon a change of control or certain termination events.

Management Comments

• "The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person."

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, common across all industries when executives receive equity compensation that vests and triggers tax obligations. It does not provide specific industry-related insights beyond the company's name.

Comparison to Industry Standards

• This type of transaction (sale for tax withholding) is a common and standard practice for executives receiving equity compensation across publicly traded companies globally.
• It aligns with typical compensation structures and tax compliance requirements, and does not indicate any deviation from industry norms.
• No specific comparable companies, projects, or results are mentioned in this filing.

Related Party Transactions

• Securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
• Securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
• Securities are held by Oyler Investment LLC, of which 99% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
• Securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is for tax purposes and not a discretionary divestment. It represents a minor reduction in the CEO's direct stake but does not signal a lack of confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued vesting of the remaining restricted share units on each anniversary of June 22, 2022, subject to continued service.

Key Dates

Keywords

BeOne Medicines Ltd., ONC, John Oyler, SEC Form 4, insider trading, stock sale, American Depositary Shares, tax withholding, restricted share units, beneficial ownership